OrbiMed
OrbiMed is a healthcare-dedicated investment firm focusing on biopharmaceuticals to medical devices and diagnostics.
Business Model:
Revenue: $13.7M
Employees: 51-200
Rankings
Industries / Tags:
Detailed OrbiMed Information
Geographic Data
Address: 601 Lexington Ave, 53rd Street
City: New York
State: NY
Zip: 10022
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$12B
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
3,764,164Website Global Rank
3,617Website Monthly Traffic
Twitter Followers
Description
OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed&s;s investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investments series of venture capital funds and a family of public equity investment funds.
Contact Phone:
+12127396400
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2018 | TytoCare | Series C | 0 |
| 12/2021 | TandemAI | Pre-Series A | 25M |
| 1/2002 | Peptimmune | Series A | 2.3M |
| 6/2007 | Athersys | Venture Round | 0 |
| 4/2018 | Synthorx | Series C | 63M |
| 2/2022 | Electra Therapeutics | Series B | 0 |
| 8/2020 | GentiBio | Seed Round | 20M |
| 8/2016 | Apollomics | Series A | 9.8M |
| 9/2017 | Realm Therapeutics | Post-IPO Equity | 26M |
| 8/2010 | ViewRay | Series C | 20M |
| 5/2020 | AbCellera | Series B | 105M |
| 2/2014 | Ornim Medical | Series B | 10M |
| 10/2018 | 89bio | Series A | 60M |
| 9/2011 | ViewRay | Debt Financing | 10M |
| 3/2020 | AbCellera Biologics | Series A | 75M |
| 5/2015 | Eyegood Ophthalmic Hospital | Series A | - |
| 3/2015 | Amoy Diagnostics | Series B | 15.6M |
| 10/2013 | Alector | Series A | - |
| 1/2021 | Delfi Diagnostics | Series A | 0 |
| 9/2012 | cCAM Biotherapeutics | Series A | - |
| 11/2008 | ARYx Therapeutics | Post-IPO Equity | 21.6M |
| 10/2020 | Zylox | Series C | 0 |
| 1/2008 | Gelesis | Series B | 16M |
| 7/2012 | Arteaus Therapeutics | Venture Round | 12M |
| 11/2016 | Suraksha Diagnostics | Venture Round | 40M |
| 11/2013 | ARMO BioSciences | Series A | 20M |
| 12/2013 | RedHill Biopharma | Post-IPO Equity | 8.5M |
| 4/2019 | Laekna Therapeutics | Series B | 27.5M |
| 7/2016 | MDClone | Seed Round | 5M |
| 8/2012 | Intercept Pharmaceuticals | Series C | 30M |
| 8/2017 | ARMO BioSciences | Series C | 0 |
| 4/2017 | SteadyMed Therapeutics | Post-IPO Equity | 0 |
| 6/2021 | Insilico Medicine | Series C | 0 |
| 6/2007 | Singulex | Series D | 19M |
| 10/2015 | SmartZyme BioPharma | Equity | 4M |
| 11/2012 | Cardioxyl Pharmaceuticals | Series B | 28M |
| 8/2021 | XtalPi | Series D | 0 |
| 6/2022 | DarioHealth | Post-IPO Debt | 50M |
| 7/2018 | Alector | Series E | 133M |
| 4/2017 | Arsanis | Series D | 0 |
| 12/2014 | Ascendis Pharma | Series D | 60M |
| 6/2020 | Prothelia | Venture Round | - |
| 10/2017 | Gemini Therapeutics | Series A | 42.5M |
| 6/2004 | ChemoCentryx | Series B | 33M |
| 12/2016 | Augmedix | Venture Round | 23M |
| 6/2004 | Emphasys Medical | Series D | 27.5M |
| 9/2001 | Predix Pharmaceuticals | Venture Round | 7.8M |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 6/2003 | CryoCor | Series C | 27.5M |
| 11/2000 | Predix Pharmaceuticals | Series A | 3M |
| 8/2005 | Cerexa Inc. | Series A | 0 |
| 9/2008 | Innovative Spinal Technologies | Series C | 18M |
| 2/2007 | Targanta Therapeutics | Series C | 70M |
| 9/2021 | Alpine Immune Sciences | Private Placement | 91M |
| 1/2019 | Alpine Immune Sciences | Post-IPO Equity | 25M |
| 2/2015 | Laxmi Dental | Venture Round | 10.1M |
| 10/2015 | SmartZyme BioPharma | Seed Round | 4M |
| 10/2011 | Puma Biotechnology | Post-IPO Equity | 55M |
| 10/2008 | Biolex Therapeutics | Series D | 0 |
| 10/2022 | Odyssey Therapeutics | Series B | 0 |
| 8/2016 | Nutrinia | Series D | 30M |
| 9/2021 | Amolyt Pharma | Series B | 0 |
| 7/2007 | Agensys | Series D | 41.3M |
| 4/2022 | Valneva | Post-IPO Debt | 20M |
| 9/2021 | Vanqua Bio | Series B | 85M |
| 10/2021 | Scout Bio | Series B | 0 |
| 5/2017 | BIOMx | Series A | 24M |
| 1/2021 | Visen Pharmaceuticals | Series B | 0 |
| 8/2021 | Humacyte | PIPE | 175M |
| 9/2017 | Uquifa | Venture Round | - |
| 2/2007 | Cerapedics | Venture Round | 12.3M |
| 12/2019 | Aspen Neuroscience | Seed Round | 0 |
| 12/2017 | Ikena Oncology | Series A | 49M |
| 8/2016 | ViewRay | Post-IPO Equity | 0 |
| 11/2007 | SGX Pharmaceuticals | Post-IPO Equity | 25M |
| 4/2007 | Sientra | Series B | 85M |
| 5/2017 | Guardant Health | Series E | 360M |
| 1/2012 | Roka Bioscience | Series D | 47.5M |
| 1/2021 | Noctrix Health | Series B | 17M |
| 3/2021 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
| 10/2015 | Audentes Therapeutics | Series C | 65M |
| 7/2021 | Entos | Series A | 0 |
| 4/2020 | TytoCare | Series D | 0 |
| 7/2015 | TytoCare | Series B | 0 |
| 11/2003 | Auxilium Pharmaceuticals | Series D | 43M |
| 10/2018 | Galecto | Series C | 90.2M |
| 8/2021 | Neurogastrx | Series B | 60M |
| 9/2022 | Adaptive Biotechnologies | Post-IPO Debt | 125M |
| 8/2005 | Adiana | Series D | 23M |
| 1/2018 | Vivimed Labs | Post-IPO Equity | 7.5M |
| 9/2017 | Vivimed Labs | Post-IPO Equity | 42.5M |
| 3/2014 | TytoCare | Series A | 7M |
| 5/2015 | Otic Pharma | Series C | - |
| 6/2014 | Dimension Therapeutics | Series A | 30M |
| 1/2005 | Predix Pharmaceuticals | Series C | 0 |
| 2/2017 | PMV Pharmaceuticals | Series B | 74M |
| 11/2012 | CardiAQ Valve Technologies | Series B | 37.3M |
| 11/2011 | DFine | Venture Round | 25M |
| 8/2006 | ChemoCentryx | Series C | 0 |
| 1/2020 | Harmony Biosciences | Debt Financing | 200M |
| 4/2021 | Arrail Dental Clinic | Series E | 0 |
| 9/2010 | Good Start Genetics | Series A | 18M |
| 12/2022 | Stairway Medical | Series A | - |
| 3/2012 | Receptos | Venture Round | 30M |
| 4/2019 | Fusion Pharmaceuticals | Series B | 0 |
| 10/2020 | BioNova Pharma | Series B | 25M |
| 12/2020 | Immvira | Series C | - |
| 8/2003 | Predix Pharmaceuticals | Series B | 0 |
| 7/2018 | Compass Therapeutics, Inc. | Series A | 0 |
| 10/2013 | Loxo Oncology | Series A | 33M |
| 8/2008 | InteKrin | Series C | 0 |
| 7/2002 | ARYx Therapeutics | Series C | 25M |
| 9/2010 | Relypsa | Series B | 70M |
| 6/2022 | MiroBio | Series B | 0 |
| 10/2022 | PIC Therapeutics | Series A | 35M |
| 4/2016 | Gemini Therapeutics | Seed Round | 2M |
| 6/2013 | Singulex | Series G | 15M |
| 12/2014 | Nutrinia | Series C | 12M |
| 7/2021 | Owlet Baby Care | Post-IPO Equity | 130M |
| 6/2021 | Biocytogen | Series E | - |
| 11/2021 | Tricida | Post-IPO Equity | 42M |
| 9/2018 | Arcutis Biotherapeutics | Series B | 58M |
| 8/2012 | Ornim Medical | Series B | 20M |
| 1/2019 | Third Harmonic Bio | Series A | 50M |
| 1/2019 | Enliven Therapeutics | Seed Round | - |
| 8/2020 | Aerin Medical | Venture Round | 48M |
| 9/2010 | NeurAxon | Debt Financing | 0 |
| 3/2002 | Agensys | Series C | 0 |
| 3/2012 | Sientra | Series C | 65M |
| 2/2021 | Evox Therapeutics | Series C | 96.7M |
| 1/2017 | scPharmaceuticals | Series B | 45.6M |
| 3/2014 | Domain Surgical | Series C | 35M |
| 4/2014 | Aerpio Pharmaceuticals | Series C | 0 |
| 11/2012 | Ambit Biosciences | Venture Round | 0 |
| 7/2021 | NeRRe Therapeutics | Series B | 0 |
| 11/2018 | Alphamab Oncology | Series A | 0 |
| 7/2017 | MobileODT | Series B | 0 |
| 12/2017 | Chemomab | Series B | 10M |
| 12/2019 | Chemomab | Series C | 20M |
| 3/2021 | Chemomab | Post-IPO Equity | 45.5M |
| 11/2021 | Alpheus Medical | Series A | 0 |
| 6/2018 | ENYO Pharma | Series B | 46.8M |
| 8/2011 | Vessix Vascular | Series B | 0 |
| 6/2006 | CoGenesys | Series A | 55M |
| 2/2012 | Otic Pharma | Series B | 4.3M |
| 1/2021 | Ikena Oncology | Series B | 0 |
| 8/2016 | Cleave Therapeutics | Series B | 0 |
| 11/2015 | TigerConnect | Series C | 0 |
| 6/2010 | Igenica | Series B | 24M |
| 5/2011 | Crown Bioscience | Series C | 28.8M |
| 2/2021 | Miaoshou Doctor | Series E | 0 |
| 6/2015 | sikka.ai | Series C | 10.5M |
| 9/2010 | Anthera Pharmaceuticals | Private Placement | 31.5M |
| 5/2021 | Binx Health | Series E | 0 |
| 7/2019 | Amolyt Pharma | Series A | 0 |
| 7/2016 | SteadyMed Therapeutics | Post-IPO Equity | 32M |
| 4/2021 | EDDA Technology | Private Equity Round | 150M |
| 5/2013 | Natera | Series E | 54.6M |
| 2/2018 | MDClone | Series A | 10M |
| 10/2007 | Cerapedics | Series A | 0 |
| 3/2022 | MDClone | Series C | 0 |
| 3/2020 | Keros Therapeutics | Series C | 0 |
| 1/2009 | Singulex | Series E | 19M |
| 2/2022 | Congruence Therapeutics | Series A | 0 |
| 3/2023 | Congruence Therapeutics | Series A | 0 |
| 5/2016 | Nucleix | Seed Round | 3M |
| 3/2018 | Crinetics Pharmaceuticals | Series B | 63.5M |
| 8/2015 | Principia Biopharma | Series B | 15.3M |
| 4/2020 | Aspen Neuroscience | Series A | 0 |
| 3/2003 | Acadia Pharmaceuticals Inc. | Series F | 25M |
| 12/2021 | Cyrus Biotechnology | Series B | 0 |
| 5/2018 | Attenua | Series A | 35M |
| 1/2022 | ImmPACT Bio | Series B | 0 |
| 2/2018 | ORIC Pharmaceuticals | Series C | 50M |
| 11/2020 | VIVUS | Post-IPO Equity | 33.6M |
| 6/2004 | Rejuvenon | Series B | 37M |
| 9/2010 | Eddingpharm (Cayman) | Series B | 24M |
| 6/2001 | Corus Pharma | Series A | 18.5M |
| 12/2021 | Odyssey Therapeutics | Series A | 0 |
| 11/2020 | Decibel Therapeutics | Series D | 82.2M |
| 3/2015 | Aeglea BioTherapeutics | Series B | 44M |
| 2/2021 | Gemini Therapeutics | Post-IPO Equity | 0 |
| 1/2007 | InteKrin | Series B | 0 |
| 8/2021 | XinThera | Series B | 50M |
| 1/2017 | ViewRay | Post-IPO Equity | 0 |
| 6/2002 | MacroGenics | Venture Round | 12.6M |
| 10/2008 | MacroGenics | Series D | 25M |
| 11/2011 | Rempex Pharmaceuticals | Series B | 67.5M |
| 10/2014 | MID Labs | Venture Round | 51M |
| 5/2021 | Caris Life Sciences | Private Equity Round | 0 |
| 7/2014 | Atox Bio | Series E | 23M |
| 1/2015 | Aduro BioTech | Series D | 51.4M |
| 1/2019 | Apollomics | Series B | 100M |
| 2/2018 | Asian Institute of Medical Sciences | Venture Round | 21M |
| 6/2020 | Mereo Biopharma | Post-IPO Equity | 0 |
| 8/2021 | Vigil Neuroscience | Series B | 0 |
| 8/2020 | MobileODT | Series C | 0 |
| 11/2019 | Akeso Biopharma | Series D | 150M |
| 12/2015 | ORIC Pharmaceuticals | Series B | 53M |
| 1/2017 | Therachon | Series A | 5M |
| 9/2017 | Sonendo | Private Equity Round | 0 |
| 6/2000 | Acadia Pharmaceuticals Inc. | Debt Financing | 0 |
| 8/2007 | Enobia Pharma | Series B | 37.8M |
| 9/2013 | Otonomy | Series C | 45.9M |
| 10/2015 | Arvinas | Series B | 41.6M |
| 9/2015 | ReViral | Series A | 21M |
| 5/2021 | Sparrow Pharmaceuticals | Series A | 50M |
| 6/2011 | Ambit Biosciences | Series D | 0 |
| 11/2011 | Cleave Therapeutics | Series A | 42M |
| 1/2018 | Neurogastrx | Series A | 45M |
| 1/2012 | Kerala Institute of Medical Sciences | Venture Round | 33.9M |
| 7/2016 | Tricida | Series C | 0 |
| 7/2012 | Vifor Pharma | Private Equity Round | 0 |
| 12/2020 | Syros Pharmaceuticals | Post-IPO Equity | 90.5M |
| 6/2021 | Stemirna | Venture Round | 0 |
| 10/2001 | GeneFormatics | Venture Round | 0 |
| 6/2016 | Alpine Immune Sciences | Series A | 48M |
| 9/2019 | Repare Therapeutics | Series B | 82.5M |
| 3/2007 | ChemoCentryx | Series D | 29.8M |
| 6/2022 | Aerin Medical | Private Equity Round | 0 |
| 5/2020 | Q32 Bio | Series A | 46M |
| 12/2000 | Molecular Staging | Series D | 41.3M |
| 6/2012 | Sonendo | Series C | 0 |
| 4/2014 | Principia Biopharma | Series B | 50M |
| 6/2019 | Acutus Medical | Series D | 0 |
| 9/2021 | iECURE | Series A | 50M |
| 6/2012 | Igenica | Series C | 33M |
| 5/2022 | Terremoto Biosciences | Series A | 0 |
| 1/2017 | Pionyr Immunotherapeutics | Series A | 8M |
| 11/2006 | Abionyx Pharma | Series B | 53.5M |
| 1/2004 | Peninsula Pharmaceuticals | Series C | 0 |
| 4/2013 | Treato | Series B | 14.5M |
| 1/2020 | Sonendo | Venture Round | 85M |
| 2/2014 | GC Aesthetics | Private Equity Round | 60M |
| 10/2015 | Netmeds | Series A | 50M |
| 1/2016 | LogicBio Therapeutics | Series A | 4M |
| 1/2016 | NextCure | Series A | 67M |
| 4/2010 | Selecta Biosciences | Series C | 15M |
| 6/2004 | ARYx Therapeutics | Series D | 55M |
| 2/2011 | Arsanis | Series A | 10M |
| 8/2015 | Avitide | Series C | 7.6M |
| 6/2020 | MabPlex International | Series B | 0 |
| 2/2021 | AnchorDx | Series C | 40M |
| 7/2020 | Perfuse Therapeutics | Venture Round | 9M |
| 12/2014 | Corvus Pharmaceuticals | Series A | 33.5M |
| 7/2005 | EUSA Pharma | Venture Round | 14M |
| 8/2005 | Amnis | Series C | 11.3M |
| 3/2006 | Arius Research | Venture Round | 21.5M |
| 2/2019 | Health Catalyst | Series F | 0 |
| 6/2014 | Medigus | Post-IPO Equity | 11.1M |
| 3/2014 | Unilife Corporation | Post-IPO Debt | 60M |
| 8/2007 | NeurAxon | Series B | 32M |
| 3/2022 | Harvest Integrated Research Organization | Series A | - |
| 7/2020 | Harbour Biomed | Series C | 0 |
| 10/2022 | Insmed | Post-IPO Debt | 500M |
| 8/2009 | Enobia Pharma | Series C | 0 |
| 3/2017 | Aerpio Pharmaceuticals | Venture Round | 0 |
| 7/2015 | ViewRay | Post-IPO Equity | 0 |
| 12/2014 | Pieris Pharmaceuticals | Post-IPO Equity | 0 |
| 9/2020 | I-Mab Biopharma | Post-IPO Equity | 0 |
| 3/2017 | Promentis Pharmaceuticals | Series C | 26M |
| 7/2020 | Compass Therapeutics, Inc. | Venture Round | 0 |
| 11/2015 | Avedro | Series E | 32M |
| 4/2017 | Avedro | Venture Round | 0 |
| 8/2012 | OmniGuide | Venture Round | 35M |
| 1/2021 | Terns Pharmaceuticals | Series C | 87M |
| 5/2015 | SI-BONE | Growth | 21M |
| 7/2022 | LifeWell | Venture Round | 80M |
| 10/2012 | Relypsa | Venture Round | 2.6M |
| 8/2011 | Relypsa | Series B | 70.1M |
| 6/2007 | EUSA Pharma | Venture Round | 0 |
| 3/2021 | Janux Therapeutics | Series A | 0 |
| 4/2014 | Sierra Oncology | Series D | 0 |
| 7/2010 | DFine | Venture Round | 36.2M |
| 8/2016 | Ornim Medical | Series C | 20M |
| 7/2013 | Audentes Therapeutics | Series A | 30M |
| 3/2020 | Rongchang Pharmaceutical | Series A | - |
| 1/2014 | Clementia Pharmaceuticals | Series A | 22.5M |
| 2/2023 | BIOMx | Post-IPO Equity | 0 |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 1/2023 | Caris Life Sciences | Debt Financing | 0 |
| 1/2015 | Clementia Pharmaceuticals | Series A | 10M |
| 4/2012 | Good Start Genetics | Series B | 14M |
| 5/2021 | Magenta Therapeutics | Post-IPO Equity | 86.4M |
| 1/2016 | Zai Lab | Series B | 106.2M |
| 10/2020 | Q32 Bio | Series B | 60M |
| 8/2010 | Complete Genomics | Series E | 39M |
| 3/2013 | Avitide | Series A | 1.4M |
| 9/2015 | Corvus Pharmaceuticals | Series B | 75M |
| 3/2019 | InventisBio | Series C | 70M |
| 12/2014 | PMV Pharmaceuticals | Series A | 30M |
| 5/2002 | Onyx Pharmaceuticals | Venture Round | 20M |
| 10/2017 | TELA Bio | Venture Round | 0 |
| 11/2006 | EUSA Pharma | Venture Round | 0 |
| 7/2012 | Cerapedics | Series C | 0 |
| 11/2012 | MethylGene | Venture Round | 26.1M |
| 10/2005 | Avanir Pharmaceuticals | Post-IPO Equity | 16.2M |
| 8/2018 | Therachon | Series B | 60M |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 12/2011 | ETHRIS | Series A | - |
| 11/2016 | Inspire Medical Systems | Series F | 0 |
| 12/2020 | Edgewise Therapeutics | Series C | 95M |
| 8/2019 | Cleave Therapeutics | Series C | 0 |
| 9/2021 | LifeCell International | Venture Round | 34.6M |
| 8/2021 | Rimag | Series D | 0 |
| 8/2021 | GentiBio | Series A | 157M |
| 8/2019 | MDClone | Series B | 26M |
| 1/2015 | GENEWIZ | Venture Round | - |
| 8/2021 | Carrot Fertility | Series C | 75M |
| 3/2021 | NewMed Medical | Series C | 100M |
| 9/2020 | Novellus | Series C | 57M |
| 8/2020 | PMV Pharmaceuticals | Series D | 70M |
| 8/2019 | GrayBug | Series C | 80M |
| 10/2018 | Bsense Bio Therapeutics | Seed Round | 405k |
| 5/2017 | Turning Point Therapeutics | Series C | 45M |
| 11/2021 | PierianDx | Growth | 30M |
| 11/2019 | Protekt Therapeutics | Venture Round | 4.1M |
| 9/2009 | PharmAbcine | Series A | 6M |
| 2/2021 | Clover Biopharmaceuticals | Series C | 230M |
| 12/2010 | Bonovo | Series C | 10M |
| 12/2016 | Sonendo | Series E | 0 |
| 10/2018 | Terns Pharmaceuticals | Series B | 80M |
| 7/2021 | Zion Pharma | Series B | 40M |
| 12/2020 | Cullinan Oncology | Series C | 131.2M |
| 3/2021 | Scribe Therapeutics | Series B | 100M |
| 9/2015 | Intellia Therapeutics | Series B | 0 |
| 9/2019 | Passage Bio | Series B | 110M |
| 6/2017 | LogicBio Therapeutics | Series B | 45M |
| 8/2008 | Glaukos | Series D | 35M |
| 6/2013 | Sonendo | Series C | 0 |
| 5/2016 | GrayBug | Series B | 44.5M |
| 8/2005 | Innovative Spinal Technologies | Series B | 39M |
| 6/2017 | Mitoconix Bio | Series A | 20M |
| 1/2022 | Beijing Tianxing | Series B | - |
| 4/2015 | Dimension Therapeutics | Series B | 65M |
| 4/2010 | Aragon Pharmaceuticals, Inc. | Series B | 22M |
| 11/2013 | Iroko Pharmaceuticals | Debt Financing | 75M |
| 5/2020 | Zentera Therapeutics | Series A | 20M |
| 4/2007 | Affimed | Series B | 32M |
| 5/2021 | Gennao Bio | Series A | 40M |
| 8/2018 | ReViral | Series B | 0 |
| 6/2021 | Adela | Series A | 60M |
| 5/2015 | Symbiomix Therapeutics | Series A | 41M |
| 10/2022 | Treeline Biosciences | Series A | 261.3M |
| 10/2013 | Seragon Pharmaceuticals | Series A | 30M |
| 9/2018 | Silverback Therapeutics | Series A | 37.5M |
| 5/2009 | Aragon Pharmaceuticals, Inc. | Series A | 8M |
| 3/2012 | Singulex | Series F | 15.3M |
| 8/2020 | Erasca | Series B | 36M |
| 6/2015 | Clementia Pharmaceuticals | Venture Round | 0 |
| 3/2020 | ReCode Therapeutics | Series A | 0 |
| 5/2019 | Athenex | Post-IPO Equity | 100M |
| 11/2008 | Pacira Pharmaceuticals | Series A | 85M |
| 12/2017 | Atox Bio | Series F | 0 |
| 10/2012 | Affimed | Series D | 20.1M |
| 7/2020 | MBX Biosciences | Series A | 34.6M |
| 1/2022 | HanBio Therapeutics | Series A | 40M |
| 6/2016 | Verona Pharma | Post-IPO Equity | 65.6M |
| 9/2015 | Therachon | Series A | 35M |
| 1/2020 | VectivBio | Series A | 35M |
| 12/2020 | Enliven Therapeutics | Series A | 55M |
| 4/2015 | Nabriva Therapeutics | Series B | 0 |
| 11/2017 | RDD Pharma | Series B | 0 |
| 9/2010 | SuperDimension | Debt | 15M |
| 8/2012 | Vifor Pharma | Series C | 0 |
| 11/2017 | Tricida | Series D | 0 |
| 3/2015 | Tricida | Series B | 0 |
| 9/2014 | Tricida | Series A | 0 |
| 7/2022 | Delfi Diagnostics | Series B | 0 |
| 3/2021 | BlossomHill Therapeutics | Series A | 71M |
| 7/2019 | Foamix | Post-IPO Debt | 64M |
| 9/2018 | Ramino Bio | Seed Round | - |
| 9/2017 | SpringWorks Therapeutics | Series A | 103M |
| 5/2014 | Keystone Heart | Series B | 0 |
| 4/2021 | Nucleix | Venture Round | 55M |
| 3/2020 | NewMed Medical | Series B | - |
| 7/2020 | Verona Pharma | Private Placement | 200M |
| 8/2015 | Syndax Pharmaceuticals | Series C | 0 |
| 9/2014 | GC-Rise Pharma | Series B | 15M |
| 8/2016 | Arrowhead Pharmaceuticals | Post-IPO Equity | 45M |
| 4/2009 | Cerapedics | Series B | 15M |
| 6/2010 | Acceleron Pharma | Venture Round | 10.3M |
| 4/2015 | True North Therapeutics | Series B | 35M |
| 10/2011 | Arteaus Therapeutics | Venture Round | 18M |
| 6/2019 | Acutus Medical | Debt Financing | 70M |
| 9/2014 | Adaptimmune | Series A | 0 |
| 9/2020 | ESCAPE Bio | Venture Round | 73M |
| 8/2022 | Disc Medicine | Post-IPO Equity | 0 |
| 7/2017 | ESCAPE Bio | Series A | 63M |
| 9/2013 | Practice Fusion | Series D | 85M |
| 10/2012 | Principia Biopharma | Series A | 12.5M |
| 8/2021 | Pulnovo Medical | Venture Round | 15.5M |
| 6/2022 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
| 1/2016 | Alector | Series D | 29.5M |
| 6/2018 | Laekna Therapeutics | Series A | 0 |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 10/2009 | Amarin | Post-IPO Equity | 70M |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 10/2005 | Salmedix | Series C | 0 |
| 9/2021 | Disc Medicine | Series B | 90M |
| 12/2014 | Audentes Therapeutics | Series B | 42.5M |
| 5/2014 | ARMO BioSciences | Series B | 30M |
| 11/2007 | Ambit Biosciences | Series D | 49.3M |
| 8/2013 | Acutus Medical | Series B | 0 |
| 6/2016 | SI-BONE | Venture Round | 26M |
| 8/2021 | Zentera Therapeutics | Series B | 75M |
| 10/2020 | Gracell Biotechnologies | Series C | 0 |
| 10/2017 | NeuroPace | Venture Round | 74M |
| 3/2019 | Imara | Series B | 0 |
| 10/2021 | PharmEasy | Venture Round | 0 |
| 8/2020 | NeuroPace | Venture Round | 33M |
| 11/2017 | resTORbio | Series A | 40M |
| 3/2019 | Prevail Therapeutics | Series B | 50M |
| 11/2020 | Cytek Biosciences | Series D | 120M |
| 7/2010 | Abionyx Pharma | Series C | 0 |
| 1/2023 | Pathalys Pharma | Series A | 0 |
| 10/2019 | Arcutis Biotherapeutics | Series C | 94.5M |
| 9/2022 | Capstan Therapeutics | Series A | 102M |
| 3/2021 | Century Therapeutics | Series C | 0 |
| 4/2015 | Natera | Series F | 0 |
| 2/2019 | Peloton Therapeutics | Series E | 0 |
| 4/2020 | Pandion Therapeutics | Series B | 80M |
| 9/2020 | Silverback Therapeutics | Series C | 85M |
| 5/2023 | Convergent Therapeutics | Series A | 0 |
| 8/2020 | ImmPACT Bio | Series A | 0 |
| 5/2013 | ViewRay | Venture Round | 15M |
| 10/2021 | WT Microtech Medical | Series E | 153M |
| 1/2016 | Guardant Health | Series D | 100M |
| 9/2020 | Galecto | Series D | 0 |
| 1/2014 | TigerConnect | Series B | 23M |
| 2/2019 | Health Catalyst | Debt Financing | 0 |
| 3/2020 | Remegen | Private Equity Round | 0 |
| 11/2022 | Alpheus Medical | Series A | 14M |
| 11/2022 | MBX Biosciences | Series B | 115M |
| 4/2018 | Arvinas | Series C | 55M |
| 10/2020 | Zhaoke Ophthalmology Pharmaceutical | Series B | 0 |
| 9/2020 | InventisBio | Series D | 0 |
| 6/2022 | Frontera Therapeutics | Series B | 0 |
| 6/2019 | Jinxin Fertility | Series F | 150M |
| 2/2021 | Nuvation Bio | Post-IPO Equity | 502M |
| 12/2022 | Apogee Therapeutics | Series B | 0 |
| 7/2011 | Roka Bioscience | Series C | 0 |
| 1/2006 | Supernus Pharmaceuticals | Series A | 27.5M |
| 8/2009 | Complete Genomics | Series D | 45M |
| 4/2023 | Aer Therapeutics | Series A | 0 |
| 3/2015 | Cynapsus Therapeutics | Venture Round | 16.6M |
| 9/2022 | ACELYRIN | Series C | 0 |
| 10/2012 | Aragon Pharmaceuticals, Inc. | Series D | 50M |
| 2/2016 | Synlogic | Series B | 40M |
| 1/2014 | Igenica | Series C | 14M |
| 3/2014 | SAGE Therapeutics | Series C | 38M |
| 4/2019 | SpringWorks Therapeutics | Series B | 125M |
| 9/2021 | Garuda Therapeutics | Series A | 72M |
| 9/2021 | ADARx Pharmaceuticals | Series B | 75M |
| 5/2023 | Magenta Medical | Venture Round | 0 |
| 12/2018 | Bellus Health | Post-IPO Equity | 26M |
| 8/2018 | KaNDy Therapeutics | Series C | 32.6M |
| 10/2014 | Invitae | Series F | 0 |
| 12/2011 | arGEN-X | Series B | 43.8M |
| 1/2016 | Adicet Bio | Series A | 51M |
| 1/2022 | Nucleix | Venture Round | 22M |
| 9/2020 | Ruipeng Pet Healthcare | Venture Round | - |
| 11/2021 | Capstan Therapeutics | Seed Round | 63M |
| 6/2016 | Iovance Biotherapeutics | Equity | 100M |
| 7/2017 | Cyrus Biotechnology | Series A | 8M |
| 9/2019 | Adicet Bio | Series B | 0 |
| 11/2022 | iECURE | Series A | 0 |
| 11/2021 | Edge Medical Robotics | Series C | 0 |
| 4/2021 | Janux Therapeutics | Series B | 0 |
| 10/2005 | Cerimon Pharmaceuticals | Series A | 70M |
| 7/2017 | Compass Therapeutics, Inc. | Series A | - |
| 8/2006 | Acceleron Pharma | Series B | 30M |
| 11/2008 | Adimab | Series C | 4M |
| 9/2015 | Selecta Biosciences | Series E | 38M |
| 10/2014 | Selecta Biosciences | Private Equity Round | 20M |
| 9/2013 | Arsanis | Series B | 20M |
| 10/2004 | MacroGenics | Series B | 30.5M |
| 9/2008 | ForteBio | Series C | 25M |
| 11/2021 | ACELYRIN | Series B | 0 |
| 5/2006 | MacroGenics | Series C | 45M |
| 9/2001 | MacroGenics | Series A | 13.5M |
| 10/2018 | Modis Therapeutics | Series A | 30M |
| 6/2017 | Avitide | Equity | 12M |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 12/2017 | Pionyr Immunotherapeutics | Series B | 0 |
| 4/2014 | Otonomy | Series D | 49M |
| 8/2020 | Chinook Therapeutics | Private Placement | 106M |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 9/2001 | Amphora Discovery | Series A | 35M |
| 2/2006 | Insulet Corporation | Series E | 0 |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 2/2013 | Glaukos | Series F | 30M |
| 2/2011 | Glaukos | Series E | 0 |
| 8/2014 | Civitas Therapeutics | Series C | 0 |
| 11/2020 | Achilles Therapeutics | Series C | 69.8M |
| 8/2020 | Kinnate Biopharma | Series C | 98M |
| 12/2020 | RayzeBio | Series B | 105M |
| 6/2023 | Upstream Bio | Series B | 0 |
| 10/2007 | Acceleron Pharma | Series C | 31M |
| 5/2014 | Loxo Oncology | Series B | 24M |
| 2/2017 | Rhythm Pharmaceuticals | Venture Round | 41M |
| 8/2015 | Rhythm Metabolic | Series A | 40M |
| 1/2017 | NeRRe Therapeutics | Series B | 28.6M |
| 4/2004 | Corus Pharma | Series C | 0 |
| 7/2020 | Adagio Therapeutics | Series A | 0 |
| 11/2020 | Adagio Therapeutics | Series B | 0 |
| 4/2021 | Treeline Biosciences | Series A | - |
| 8/2019 | ORIC Pharmaceuticals | Series D | 0 |
| 6/2021 | Nautilus Biotechnology | Post-IPO Equity | 0 |
| 1/2008 | ViewRay | Series B | 25M |
| 12/2013 | ViewRay | Venture Round | 0 |
| 3/2012 | ViewRay | Series C | 45M |
| 3/2023 | TandemAI | Series A | 0 |
| 2/2021 | Yisheng Biopharma | Series B | 0 |
| 11/2016 | Turnstone Biologics | Series B | 0 |
| 6/2022 | CHARM Therapeutics | Series A | 0 |
| 7/2021 | Turnstone Biologics | Series D | 0 |
| 10/2020 | Caris Life Sciences | Private Equity Round | 0 |
| 5/2014 | Inspire Medical Systems | Series E | 0 |
| 12/2015 | True North Therapeutics | Series C | 40M |
| 9/2020 | Fore Biotherapeutics | Series C | 57M |
| 9/2010 | SuperDimension | Equity | 9.8M |
| 6/2017 | Zai Lab | Series C | 30M |
| 3/2021 | Ventyx Biosciences | Series A | 0 |
| 9/2020 | BioShin | Series A | 60M |
| 9/2020 | Eledon Pharmaceuticals | Post-IPO Equity | 108M |
| 7/2020 | VelosBio | Series B | 137M |
| 2/2022 | Star Therapeutics | Venture Round | 0 |
| 12/2021 | Emergence Therapeutics | Series A | 0 |
| 3/2021 | Crossover Health | Series D | 0 |
| 4/2018 | Constellation Pharmaceuticals | Series F | 0 |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 6/2021 | RayzeBio | Series C | 108M |
| 9/2015 | Alector | Series C | 32M |
| 11/2019 | PMV Pharmaceuticals | Series C | 0 |
| 3/2020 | Silverback Therapeutics | Series B | 0 |
| 1/2021 | Scorpion Therapeutics | Series B | 162M |
| 4/2021 | Theseus Pharmaceuticals | Series B | 0 |
| 12/2019 | Kinnate Biopharma | Series B | 74.5M |
| 1/2022 | Alterome Therapeutics | Series A | 0 |
| 10/2018 | Turning Point Therapeutics | Equity | 80M |
| 11/2022 | Alterome Therapeutics | Series A | 0 |
| 8/2021 | Miaoshou Doctor | Series F | 0 |
| 5/2017 | InventisBio | Series B | 19M |
| 6/2021 | ArriVent Biopharma | Series A | 81M |
| 5/2018 | Avedro | Series F | 0 |
| 1/2021 | Abbisko Therapeutics | Series D | 123M |
| 11/2022 | Pulnovo Medical | Venture Round | - |
| 2/2022 | ArriVent Biopharma | Series A | 69M |
| 11/2018 | Harpoon Therapeutics | Series C | 70M |
| 1/2023 | ADARx Pharmaceuticals | Series B | 0 |
| 4/2021 | Adagio Therapeutics | Series C | 0 |
| 11/2018 | NextCure | Series B | 93M |
| 2/2013 | BiolineRx | Post-IPO Equity | 8M |
| 5/2011 | Biodel | Post-IPO Equity | 30M |
| 3/2018 | SmartZyme BioPharma | Series B | - |
| 8/2014 | Sonendo | Series D | 0 |
| 5/2021 | Splisense | Series B | 0 |
| 4/2022 | Sionna Therapeutics | Series B | 0 |
| 4/2011 | SMT Research and Development | Venture Round | 10.5M |
| 6/2016 | Fore Biotherapeutics | Venture Round | 2.5M |
| 6/2018 | Theseus Pharmaceuticals | Series A | 20M |
| 6/2017 | Tisbury Pharmaceuticals | Series A | 32M |
| 12/2001 | Amnis | Venture Round | 8.8M |
| 10/2019 | Silverback Therapeutics | Convertible Note | 10M |
| 10/2014 | Rapid Pathogen Screening | Debt Financing | 28M |
| 1/2016 | UPPER | Series A | 1.5M |
| 12/2022 | ArriVent Biopharma | Series B | 0 |
| 5/2017 | Xtant Medical | Post-IPO Debt | 15M |
| 4/2018 | Foamix | Post-IPO Equity | 16M |
| 11/2015 | ObsEva | Series B | 58.9M |
| 10/2020 | Azura Ophthalmics | Private Equity Round | 20M |
| 10/2017 | Azura Ophthalmics | Series B | 16M |
| 9/2016 | Chemomab | Series A | 5M |
| 8/2012 | Whale Imaging | Series A | 8M |
| 7/2020 | New Horizon Health | Series E | 30M |
| 10/2014 | Unilife Corporation | Post-IPO Debt | 10M |
| 3/2016 | Acutus Medical | Series C | 75M |
| 3/2022 | Harvest Integrated Research Organization | Series A | 1.6M |
| 8/2020 | Prelude Therapeutics | Series C | 50M |
| 1/2001 | NeoGenesis Pharmaceuticals | Venture Round | 23M |
| 12/2009 | Manipal Acunova | Series B | - |
| 4/2020 | TransMedics | Post-IPO Debt | 2.2M |
| 2/2019 | BIOMx | Series B | 0 |
| 1/2016 | Eurolife Healthcare Pvt Ltd | Venture Round | - |
| 1/2010 | Adimab | Series D | 8.2M |
| 10/2020 | Olema Oncology | Series C | 85M |
| 5/2017 | Synlogic | Series C | 42M |
| 4/2016 | Kala Pharmaceuticals | Series C | 68M |
| 6/2005 | SuperDimension | Series B | 27M |
| 6/2019 | Prelude Therapeutics | Series B | 60M |
| 5/2018 | Sublimity Therapeutics | Venture Round | 64M |
| 3/2018 | Prevail Therapeutics | Series A | 75M |
| 6/2010 | angelalign | Series A | 6.6M |
| 7/2020 | Cogent Biosciences | Post-IPO Equity | 104.4M |
| 6/2022 | Upstream Bio | Series A | 200M |
| 9/2014 | Affimed | Series E | 0 |
| 10/2020 | VectivBio | Equity | 110M |
| 6/2003 | CryoCor | Series D | 46M |
| 8/2020 | ReViral | Series C | 0 |
| 9/2019 | Edgewise Therapeutics | Series B | 50M |
| 10/2022 | VectivBio | Post-IPO Equity | 0 |
| 4/2014 | SI-BONE | Venture Round | 33M |
| 11/2020 | Dami&a;Xiaomi | Series C | 1.5M |
| 5/2023 | Magenta Medical | Venture Round | 0 |
| 5/2023 | Convergent Therapeutics | Series A | 0 |
| 4/2023 | Aer Therapeutics | Series A | 0 |
| 3/2023 | Congruence Therapeutics | Series A | 0 |
| 3/2023 | TandemAI | Series A | 0 |
| 2/2023 | BIOMx | Post-IPO Equity | 0 |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 1/2023 | ADARx Pharmaceuticals | Series B | 0 |
| 1/2023 | Caris Life Sciences | Debt Financing | 0 |
| 1/2023 | Pathalys Pharma | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
